Emily K Ninmer

4PUBLICATIONS
20CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 10, 2026
Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).

Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan

|Mar 18, 2026
Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Emily K Ninmer, Hong Zhu, Amrita Sarkar

|Mar 03, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Emily K Ninmer, Gina R Petroni, Brian R Gastman

|Jun 19, 2025
Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial.

Emily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock

Pageof 1

Frequent Collaborators

3 joint publications

Craig L Slingluff

2 joint publications

Timothy N J Bullock

2 joint publications

Kimberly A Chianese-Bullock

1 joint publications

Hong Zhu